Lam Research Corp. Stock Rises 4.9%, Outperforms Market
Dow Jones2026/09/21 20:34This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Lam Research Corp. advanced 4.9% to $302.28 on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 1.5% to 7,764.70 and the Dow Jones Industrial Average rising 0.7% to 52,048.83.
This was the stock's third consecutive day of gains.
Lam Research Corp. closed 31.1% short of its 52-week high of $438.50, which the company achieved on June 30th.
The stock demonstrated a mixed performance when compared to some of its peers, as Advanced Micro Devices Inc. rose 9.9% to $615.52, Applied Materials Inc. rose 4.4% to $464.24, and Analog Devices Inc. rose 1.94% to $383.00.
Trading volume totaled 11.2 million, compared to the 50-day average of 9.6 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
September 21, 2026 16:34 ET (20:34 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BNP Paribas gives Microsoft (MSFT.US) a "Buy" rating: Azure price increases will be gradually implemented after contract renewals, and a deal with SpaceX may be announced soon.
BNP Paribas has rated Microsoft as "Buy" with a target price of $549.
Iranian President will head to New York for UN meeting
"Big Short" Burry opens a position in QXO (QXO.US), betting on building products integration and undervaluation; stock price rises over 7%
Investor Michael Burry disclosed that he has purchased common and preferred shares of QXO (QXO.US), a building products company, citing its integration strategy and the currently depressed stock price. The stock surged 7.2% on Monday.
700,000 new elderly patients join, Eli Lilly (LLY.US) dominates 70%: The first Medicare weight loss drug coverage report released
Dave Ricks, CEO of Eli Lilly (LLY.US), said in an interview on Monday that since Medicare began coverage for obesity drugs in July, 700,000 new elderly patients have started using GLP-1 medications.
Crypto prices
More
